2025 Q4 -tulosraportti
48 päivää sitten
‧29 min
5,9895 NOK/osake
Viimeisin osinko
0,00%Tuotto/v
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 300 | - | - | ||
| 300 | - | - | ||
| 8 | - | - | ||
| 544 | - | - | ||
| 764 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 23.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 28.10.2025 | ||
2025 Q2 -tulosraportti 14.8.2025 | ||
2025 Q1 -tulosraportti 30.4.2025 | ||
2024 Q4 -tulosraportti 12.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 päivä sittenIt is a bit puzzling that this stock has gone from being in a nice long-term rising trend a few years ago, to now the opposite, and is constantly setting new record lows, for unknown reasons. For the last 3 years, this stock has been a negative mirror image of the OSEBX index. It has now more than halved in 3 years. Why?
·1 päivä sittenUnfortunately, I don't think it's that enigmatic. There are several factors recently that have been contrary to the trend they started with at the turn of the year 2020/2021. 1. Fictitious (read unrealistic) interest income from loans to observe medical which has masked actual interest expense for bank loans. 2. Delays related to Flexilev compared to the original plan. I am curious about the growth going forward here. 3. An expensive acquisition (can become profitable in the long run, but expensive in isolation), where a large share issue was made at a low price. The shares that were issued were at much lower multiples than the acquisition, which has a dilutive effect. 4. Revenue growth has been much lower (more or less flat every quarter) than what was expected. The exception is Q4 2025. The severance package Lars received was probably to more or less force him out without "firing him". I am optimistic about the new CFO and the measures being shown now. I believe we will return to old heights, but we must now (unfortunately) account for a much larger number of outstanding shares after the last share issue. Now, the first priority in terms of financials is to repay outstanding loans where there is a concrete plan leading up to maturity. If the share price has not moved by the time the loans are repaid, I hope the company buys back shares at these prices again to reverse bad decisions.
·8 t sittenThanks to both of you for your input, good explanations from both. Nava has taken some hits, but that it should have fallen as much as it has, I think seems a bit overdramatic.- ·6.3. · MuokattuPHO: mCap 1850 mill, Rev 533 mill GENT: mCap 609 mill, Rev 176 mill NAVA: mCap 496 mill, Rev 565 mill I am aware that NAVA scores low on EBIT, but there is probably a lot of future expectation in e.g. the PHO share price. Something that seems absent in the NAVA share price. Under-analyzed, unpopular, and undervalued?
- ·5.3.28 kroner? It's only a couple of months since it was at 26. And just over 4 months since Nornes' price target was 40. What has gone so terribly wrong since then? Apart from nervous markets due to the orange genius in the White House and an unpopular sector on the Oslo Stock Exchange. We have a new and sought-after chairman, good growth, and insider buying by the CFO. I see no reason why NAVA shouldn't deliver well in 2026 too.
·4.3.Anonymbruker 27. Feb. According to AI, it is Kistefoss that has block-sold its stake to institutional investors., and the rest a bit around, hence insider trading¤ No, Kistefos (Sveaas) has only extended its forward contracts to a new date, and is still the owner of 7,413,195 shares and the position as clearly largest shareholder in Nava, almost 30.9%. This was a flagging notification, not insider trading.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
48 päivää sitten
‧29 min
5,9895 NOK/osake
Viimeisin osinko
0,00%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenIt is a bit puzzling that this stock has gone from being in a nice long-term rising trend a few years ago, to now the opposite, and is constantly setting new record lows, for unknown reasons. For the last 3 years, this stock has been a negative mirror image of the OSEBX index. It has now more than halved in 3 years. Why?·1 päivä sittenUnfortunately, I don't think it's that enigmatic. There are several factors recently that have been contrary to the trend they started with at the turn of the year 2020/2021. 1. Fictitious (read unrealistic) interest income from loans to observe medical which has masked actual interest expense for bank loans. 2. Delays related to Flexilev compared to the original plan. I am curious about the growth going forward here. 3. An expensive acquisition (can become profitable in the long run, but expensive in isolation), where a large share issue was made at a low price. The shares that were issued were at much lower multiples than the acquisition, which has a dilutive effect. 4. Revenue growth has been much lower (more or less flat every quarter) than what was expected. The exception is Q4 2025. The severance package Lars received was probably to more or less force him out without "firing him". I am optimistic about the new CFO and the measures being shown now. I believe we will return to old heights, but we must now (unfortunately) account for a much larger number of outstanding shares after the last share issue. Now, the first priority in terms of financials is to repay outstanding loans where there is a concrete plan leading up to maturity. If the share price has not moved by the time the loans are repaid, I hope the company buys back shares at these prices again to reverse bad decisions.·8 t sittenThanks to both of you for your input, good explanations from both. Nava has taken some hits, but that it should have fallen as much as it has, I think seems a bit overdramatic.
- ·6.3. · MuokattuPHO: mCap 1850 mill, Rev 533 mill GENT: mCap 609 mill, Rev 176 mill NAVA: mCap 496 mill, Rev 565 mill I am aware that NAVA scores low on EBIT, but there is probably a lot of future expectation in e.g. the PHO share price. Something that seems absent in the NAVA share price. Under-analyzed, unpopular, and undervalued?
- ·5.3.28 kroner? It's only a couple of months since it was at 26. And just over 4 months since Nornes' price target was 40. What has gone so terribly wrong since then? Apart from nervous markets due to the orange genius in the White House and an unpopular sector on the Oslo Stock Exchange. We have a new and sought-after chairman, good growth, and insider buying by the CFO. I see no reason why NAVA shouldn't deliver well in 2026 too.
- ·4.3.Anonymbruker 27. Feb. According to AI, it is Kistefoss that has block-sold its stake to institutional investors., and the rest a bit around, hence insider trading¤ No, Kistefos (Sveaas) has only extended its forward contracts to a new date, and is still the owner of 7,413,195 shares and the position as clearly largest shareholder in Nava, almost 30.9%. This was a flagging notification, not insider trading.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 300 | - | - | ||
| 300 | - | - | ||
| 8 | - | - | ||
| 544 | - | - | ||
| 764 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 23.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 28.10.2025 | ||
2025 Q2 -tulosraportti 14.8.2025 | ||
2025 Q1 -tulosraportti 30.4.2025 | ||
2024 Q4 -tulosraportti 12.2.2025 |
2025 Q4 -tulosraportti
48 päivää sitten
‧29 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 23.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 28.10.2025 | ||
2025 Q2 -tulosraportti 14.8.2025 | ||
2025 Q1 -tulosraportti 30.4.2025 | ||
2024 Q4 -tulosraportti 12.2.2025 |
5,9895 NOK/osake
Viimeisin osinko
0,00%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenIt is a bit puzzling that this stock has gone from being in a nice long-term rising trend a few years ago, to now the opposite, and is constantly setting new record lows, for unknown reasons. For the last 3 years, this stock has been a negative mirror image of the OSEBX index. It has now more than halved in 3 years. Why?·1 päivä sittenUnfortunately, I don't think it's that enigmatic. There are several factors recently that have been contrary to the trend they started with at the turn of the year 2020/2021. 1. Fictitious (read unrealistic) interest income from loans to observe medical which has masked actual interest expense for bank loans. 2. Delays related to Flexilev compared to the original plan. I am curious about the growth going forward here. 3. An expensive acquisition (can become profitable in the long run, but expensive in isolation), where a large share issue was made at a low price. The shares that were issued were at much lower multiples than the acquisition, which has a dilutive effect. 4. Revenue growth has been much lower (more or less flat every quarter) than what was expected. The exception is Q4 2025. The severance package Lars received was probably to more or less force him out without "firing him". I am optimistic about the new CFO and the measures being shown now. I believe we will return to old heights, but we must now (unfortunately) account for a much larger number of outstanding shares after the last share issue. Now, the first priority in terms of financials is to repay outstanding loans where there is a concrete plan leading up to maturity. If the share price has not moved by the time the loans are repaid, I hope the company buys back shares at these prices again to reverse bad decisions.·8 t sittenThanks to both of you for your input, good explanations from both. Nava has taken some hits, but that it should have fallen as much as it has, I think seems a bit overdramatic.
- ·6.3. · MuokattuPHO: mCap 1850 mill, Rev 533 mill GENT: mCap 609 mill, Rev 176 mill NAVA: mCap 496 mill, Rev 565 mill I am aware that NAVA scores low on EBIT, but there is probably a lot of future expectation in e.g. the PHO share price. Something that seems absent in the NAVA share price. Under-analyzed, unpopular, and undervalued?
- ·5.3.28 kroner? It's only a couple of months since it was at 26. And just over 4 months since Nornes' price target was 40. What has gone so terribly wrong since then? Apart from nervous markets due to the orange genius in the White House and an unpopular sector on the Oslo Stock Exchange. We have a new and sought-after chairman, good growth, and insider buying by the CFO. I see no reason why NAVA shouldn't deliver well in 2026 too.
- ·4.3.Anonymbruker 27. Feb. According to AI, it is Kistefoss that has block-sold its stake to institutional investors., and the rest a bit around, hence insider trading¤ No, Kistefos (Sveaas) has only extended its forward contracts to a new date, and is still the owner of 7,413,195 shares and the position as clearly largest shareholder in Nava, almost 30.9%. This was a flagging notification, not insider trading.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 300 | - | - | ||
| 300 | - | - | ||
| 8 | - | - | ||
| 544 | - | - | ||
| 764 | - | - |
Välittäjätilasto
Dataa ei löytynyt